Lead Product(s): Ex-vivo Engineered Cell Therapies
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy
Deal Size: $1,200.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration August 24, 2021
Under this new partnership, Vertex will receive rights to use Arbor’s technology to research and develop ex vivo engineered cell therapies towards Vertex’s goal of generating fully differentiated, insulin-producing hypoimmune islet cells for the treatment of type 1 diabetes.